dr. rafii discusses clinical outcomes with olaparib in patients with ovarian cancer
Published 9 years ago • 565 plays • Length 2:21Download video MP4
Download video MP3
Similar videos
-
1:29
significant factors of clinical outcomes with olaparib in patients with ovarian cancer
-
2:07
maintenance olaparib in patients with ovarian cancer
-
11:22
olaparib in ovarian cancer
-
1:20
dr. ledermann discusses olaparib in ovarian cancer
-
1:38
dr. liu on cediranib/olaparib in recurrent ovarian cancer
-
0:40
dr. willmott on fda approval of maintenance olaparib in ovarian cancer
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
1:25
olaparib in ovarian cancer
-
1:54
dr. matulonis on toxicities with olaparib for patients with ovarian cancer
-
0:43
efficacy of niraparib on pfs in patients with recurrent ovarian cancer
-
4:40
solo-1 and parp inhibitors in ovarian cancer
-
1:38
dr. chase on niraparib as frontline maintenance therapy in ovarian cancer
-
6:03
olaparib maintenance for recurrent ovarian cancer
-
1:17
dr. kristeleit on the efficacy of rucaparib in ovarian cancer
-
0:53
dr. annunziata on olaparib and cediranib combination in ovarian cancer
-
2:18
#esmo21 highlights on maintenance olaparib in ovarian cancer previously treated with parpi
-
3:25
ovarian cancer: recurrence after parp inhibition
-
0:57
dr. westin on parp resistance in ovarian cancer
-
0:49
dr. tung discusses the role of olaparib in breast cancer